Eli Lilly & Co logo

Eli Lilly & Co (LLY)

Market Closed
17 Jan, 20:00
NYSE NYSE
$
725. 72
-31.88
-4.21%
Pre Market
$
728. 05
+2.33 +0.32%
669.91B Market Cap
104.2 P/E Ratio
0.09% Div Yield
5,498,500 Volume
6.64 Eps
$ 757.6
Previous Close
Day Range
725.01 755.28
Year Range
612.7 972.53
Earnings results expected in 15 days

Summary

LLY closed Friday lower at $725.72, a decrease of 4.21% from Thursday's close, completing a monthly decrease of -7.03% or $54.87. Over the past 12 months, LLY stock lost -7.03%.
LLY pays dividends to its shareholders, with the most recent payment made on Dec 10, 2024. The next announced payment will be in In 1 month on Mar 10, 2025 for a total of $1.5.
The last earnings report, released on Oct 30, 2024, missed the consensus estimates by -0.29%. On average, the company has surpassed earnings expectations by 0.38%, based on the last three reports. The next scheduled earnings report is due on Feb 04, 2025.
The stock of the company had never split.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

LLY Chart

FAQ

What Is the Eli Lilly & Co(LLY) Stock Price Today?

The LLY stock price today is $725.72.

What Stock Exchange Does Eli Lilly & Co Trade On?

Eli Lilly & Co is listed and trades on the NYSE.

What Is the Stock Symbol for Eli Lilly & Co?

The stock symbol for Eli Lilly & Co is "LLY".

Does Eli Lilly & Co Pay Dividends? What's The Current Dividend Yield?

LLY is not paying dividends to its shareholders.

What Is the Eli Lilly & Co Market Cap?

As of today, Eli Lilly & Co market cap is 669.91B.

What is Eli Lilly & Co Earnings Per Share?

The Eli Lilly & Co EPS is 0.

What Is the Next Eli Lilly & Co Earnings Date?

Eli Lilly & Co will release its next earnings report on Feb 04, 2025.

Did Eli Lilly & Co had any splits?

No, Eli Lilly & Co has never had a stock split.

Eli Lilly & Co Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. David A. Ricks CEO
NYSE Exchange
US5324571083 ISIN
United States Country
43,000 Employees
14 Feb 2025 Last Dividend
- Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000